Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives $7.00 Consensus PT from Analysts

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) have received a consensus rating of "Hold" from the five analysts that are currently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $7.00.

A number of brokerages recently issued reports on MIST. HC Wainwright upgraded Milestone Pharmaceuticals to a "buy" rating and set a $5.00 price target on the stock in a report on Thursday, June 5th. TD Securities downgraded Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Cowen downgraded Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Finally, TD Cowen downgraded Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 1st.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MIST. Bay Rivers Group bought a new position in shares of Milestone Pharmaceuticals during the 2nd quarter valued at about $28,000. Propel Bio Management LLC bought a new position in shares of Milestone Pharmaceuticals in the 1st quarter valued at about $1,161,000. Walleye Capital LLC bought a new position in shares of Milestone Pharmaceuticals in the 1st quarter valued at about $74,000. XTX Topco Ltd lifted its holdings in shares of Milestone Pharmaceuticals by 52.7% in the 1st quarter. XTX Topco Ltd now owns 52,004 shares of the company's stock valued at $42,000 after acquiring an additional 17,950 shares during the last quarter. Finally, Toronto Dominion Bank bought a new position in shares of Milestone Pharmaceuticals in the 4th quarter valued at about $1,770,000. Institutional investors own 86.18% of the company's stock.

Milestone Pharmaceuticals Trading Down 39.1%

Shares of MIST traded down $1.00 during trading hours on Friday, hitting $1.56. The company had a trading volume of 21,182,063 shares, compared to its average volume of 1,059,143. The firm has a market cap of $83.40 million, a P/E ratio of -2.00 and a beta of 0.96. The stock's 50 day moving average price is $1.65 and its 200 day moving average price is $1.69. The company has a quick ratio of 4.67, a current ratio of 4.67 and a debt-to-equity ratio of 4.06. Milestone Pharmaceuticals has a 52-week low of $0.63 and a 52-week high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.12). On average, research analysts predict that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.